16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sphingolipid desaturase DEGS1 is essential for mitochondria-associated membrane integrity

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sphingolipids function as membrane constituents and signaling molecules, with crucial roles in human diseases, from neurodevelopmental disorders to cancer, best exemplified in the inborn errors of sphingolipid metabolism in lysosomes. The dihydroceramide desaturase Δ4-dihydroceramide desaturase 1 (DEGS1) acts in the last step of a sector of the sphingolipid pathway, de novo ceramide biosynthesis. Defects in DEGS1 cause the recently described hypomyelinating leukodystrophy-18 (HLD18) (OMIM #618404). Here, we reveal that DEGS1 is a mitochondria-associated endoplasmic reticulum membrane–resident (MAM-resident) enzyme, refining previous reports locating DEGS1 at the endoplasmic reticulum only. Using patient fibroblasts, multiomics, and enzymatic assays, we show that DEGS1 deficiency disrupts the main core functions of the MAM: (a) mitochondrial dynamics, with a hyperfused mitochondrial network associated with decreased activation of dynamin-related protein 1; (b) cholesterol metabolism, with impaired sterol O-acyltransferase activity and decreased cholesteryl esters; (c) phospholipid metabolism, with increased phosphatidic acid and phosphatidylserine and decreased phosphatidylethanolamine; and (d) biogenesis of lipid droplets, with increased size and numbers. Moreover, we detected increased mitochondrial superoxide species production in fibroblasts and mitochondrial respiration impairment in patient muscle biopsy tissues. Our findings shed light on the pathophysiology of HLD18 and broaden our understanding of the role of sphingolipid metabolism in MAM function.

          Related collections

          Most cited references72

          • Record: found
          • Abstract: found
          • Article: not found

          Dynamics and functions of lipid droplets

          Lipid droplets are storage organelles at the centre of lipid and energy homeostasis. They have a unique architecture consisting of a hydrophobic core of neutral lipids, which is enclosed by a phospholipid monolayer that is decorated by a specific set of proteins. Originating from the endoplasmic reticulum, lipid droplets can associate with most other cellular organelles through membrane contact sites. It is becoming apparent that these contacts between lipid droplets and other organelles are highly dynamic and coupled to the cycles of lipid droplet expansion and shrinkage. Importantly, lipid droplet biogenesis and degradation, as well as their interactions with other organelles, are tightly coupled to cellular metabolism and are critical to buffer the levels of toxic lipid species. Thus, lipid droplets facilitate the coordination and communication between different organelles and act as vital hubs of cellular metabolism.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Reactive Oxygen Species (ROS)-Based Nanomedicine

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mitochondrial membrane potential.

              The mitochondrial membrane potential (ΔΨm) generated by proton pumps (Complexes I, III and IV) is an essential component in the process of energy storage during oxidative phosphorylation. Together with the proton gradient (ΔpH), ΔΨm forms the transmembrane potential of hydrogen ions which is harnessed to make ATP. The levels of ΔΨm and ATP in the cell are kept relatively stable although there are limited fluctuations of both these factors that can occur reflecting normal physiological activity. However, sustained changes in both factors may be deleterious. A long-lasting drop or rise of ΔΨm vs normal levels may induce unwanted loss of cell viability and be a cause of various pathologies. Among other factors, ΔΨm plays a key role in mitochondrial homeostasis through selective elimination of dysfunctional mitochondria. It is also a driving force for transport of ions (other than H+) and proteins which are necessary for healthy mitochondrial functioning. We propose additional potential mechanisms for which ΔΨm is essential for maintenance of cellular health and viability and provide recommendations how to accurately measure ΔΨm in a cell and discuss potential sources of artifacts.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Clin Invest
                J Clin Invest
                J Clin Invest
                The Journal of Clinical Investigation
                American Society for Clinical Investigation
                0021-9738
                1558-8238
                15 May 2023
                15 May 2023
                15 May 2023
                : 133
                : 10
                : e162957
                Affiliations
                [1 ]Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
                [2 ]Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
                [3 ]Department of Paediatric Neurology, Reference Centre for Neurogenetic Diseases, Armand Trousseau–La Roche Guyon University Hospital, and I2-D2 Federation, Sorbonne-Université, Paris, France.
                [4 ]Neurometabolic Unit and Synaptic Metabolism Lab, Neurology and Pathology Department, Institut Pediàtric de Recerca, Hospital Sant Joan de Déu, and MetabERN, Barcelona, Catalonia, Spain.
                [5 ]Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
                [6 ]Josep Carreras Leukaemia Research Institute Barcelona, Catalonia, Spain.
                [7 ]Armand Trousseau–La Roche Guyon University Hospital, Sorbonne-Université, Paris, France.
                [8 ]ICFO–Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Castelldefels, Barcelona, Catalonia, Spain.
                [9 ]Departments of Neurology and Pediatrics, The Kennedy Krieger Institute, and Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
                [10 ]Department of Pathology and Experimental Therapeutics, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
                [11 ]Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L’Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
                [12 ]Departament de Medicina Experimental, Universitat de Lleida–Institut de Recerca Biomedica de Lleida, Lleida, Catalonia, Spain.
                [13 ]Department of Neurology, Columbia University Medical Center, New York, New York, USA.
                [14 ]Centro de Investigaciones Biológicas “Margarita Salas,” Madrid, Spain.
                [15 ]Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Catalonia, Spain.
                Author notes
                Address correspondence to: Aurora Pujol, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Gran Via 199, 08908 L’Hospitalet de Llobregat, Barcelona, Catalonia, Spain. Phone: 34.932607137; Email: apujol@ 123456idibell.cat .
                Author information
                http://orcid.org/0000-0002-2586-0897
                http://orcid.org/0000-0002-7498-217X
                http://orcid.org/0000-0001-5024-1396
                http://orcid.org/0000-0002-2560-3970
                http://orcid.org/0000-0003-0466-2653
                http://orcid.org/0000-0002-8031-5007
                http://orcid.org/0000-0003-1170-2676
                http://orcid.org/0000-0002-3032-014X
                http://orcid.org/0000-0001-9678-8717
                http://orcid.org/0000-0002-3129-1213
                http://orcid.org/0000-0001-9853-688X
                http://orcid.org/0000-0001-9888-8754
                Article
                162957
                10.1172/JCI162957
                10178845
                36951944
                42245720-d7ec-4fb0-8ea3-3fae72311bfa
                © 2023 Planas-Serra et al.

                This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 23 June 2022
                : 22 March 2023
                Funding
                Funded by: Instituto de Salud Carlos III, https://doi.org/10.13039/501100004587;
                Award ID: PI20/00758,P118/00111,FI18/00141,PI20-0155,CPII16/00016
                Funded by: Fundació la Marató de TV3, https://doi.org/10.13039/100008666;
                Award ID: 202006-30
                Funded by: URDCat Programme
                Award ID: SLT002/16/00174
                Funded by: Centre for Biomedical Research on Rare Diseases
                Award ID: ACCI19-759
                Funded by: Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia
                Award ID: 2021SGR00899
                Funded by: Spanish Ministerio de Economía y Competitividad
                Award ID: CEX2019-000910-S
                Categories
                Research Article

                metabolism,neuroscience,bioenergetics,demyelinating disorders,lipid rafts

                Comments

                Comment on this article